Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443652 | 0.93 | AAK1 (0.39) | ALDH1A1KDM4ESMN1; SMN2PDCD1LG2CD274 | |
| SCHEMBL5149760 | 0.76 | ABL1 (0.33) | — | |
| SCHEMBL31214287 | 0.74 | ALDH1A1 (0.47) | ALDH1A1KDM4ESMN1; SMN2PIN1P2RX3 | |
| SCHEMBL4071074 | 0.71 | KMT2A (0.37) | — | |
| SCHEMBL25283172 | 0.69 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA | |
| SCHEMBL1442896 | 0.69 | PDGFRB (0.39) | ALDH1A1KDM4ESMN1; SMN2PIN1PDGFRB | |
| Hydrazine SCHEMBL27895468 | 0.68 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2PIN1P2RX3 | |
| SCHEMBL30151419 | 0.68 | KDM4E (0.52) | ALDH1A1KDM4ESMN1; SMN2PIN1P2RX3 | |
| SCHEMBL840684 | 0.68 | KDM4E (0.52) | ALDH1A1KDM4ESMN1; SMN2PIN1P2RX3 | |
| SCHEMBL145005 | 0.67 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2PIN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2473486-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | ALDH1A1 2446/4885KDM4E 3527/4885SMN1; SMN2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.